Selecta Biosciences (SELB) Shares Down 17.6% After Analyst Downgrade

Share on StockTwits

Shares of Selecta Biosciences Inc (NASDAQ:SELB) dropped 17.6% during trading on Tuesday after Canaccord Genuity lowered their price target on the stock from $25.00 to $13.00. Canaccord Genuity currently has a buy rating on the stock. Selecta Biosciences traded as low as $2.35 and last traded at $2.52. Approximately 1,583,434 shares were traded during trading, an increase of 143% from the average daily volume of 651,536 shares. The stock had previously closed at $3.06.

Several other research analysts have also issued reports on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $7.00 target price on shares of Selecta Biosciences in a research report on Friday, March 15th. Mizuho reduced their target price on Selecta Biosciences to $4.00 and set a “buy” rating on the stock in a research report on Monday, February 4th. Needham & Company LLC reduced their target price on Selecta Biosciences to $12.00 and set a “buy” rating on the stock in a research report on Monday, January 28th. ValuEngine lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, Zacks Investment Research lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 10th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $11.61.

In other news, Director Amir Nashat purchased 1,166,666 shares of the company’s stock in a transaction on Friday, January 25th. The shares were acquired at an average price of $1.50 per share, for a total transaction of $1,749,999.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 25.20% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. Barclays PLC grew its stake in Selecta Biosciences by 87.6% during the 4th quarter. Barclays PLC now owns 12,661 shares of the company’s stock valued at $34,000 after purchasing an additional 5,911 shares during the last quarter. Rhumbline Advisers grew its stake in Selecta Biosciences by 50.3% during the 4th quarter. Rhumbline Advisers now owns 23,802 shares of the company’s stock valued at $63,000 after purchasing an additional 7,965 shares during the last quarter. Two Sigma Advisers LP grew its stake in Selecta Biosciences by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock valued at $146,000 after purchasing an additional 8,500 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Selecta Biosciences during the 3rd quarter valued at about $196,000. Finally, MetLife Investment Advisors LLC purchased a new stake in Selecta Biosciences during the 3rd quarter valued at about $225,000. Institutional investors and hedge funds own 46.73% of the company’s stock.

The company has a market cap of $68.76 million, a price-to-earnings ratio of -0.92 and a beta of 1.55.

Selecta Biosciences (NASDAQ:SELB) last issued its earnings results on Friday, March 15th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.10. The company had revenue of $0.90 million during the quarter. As a group, research analysts expect that Selecta Biosciences Inc will post -1.7 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Selecta Biosciences (SELB) Shares Down 17.6% After Analyst Downgrade” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4236580/selecta-biosciences-selb-shares-down-17-6-after-analyst-downgrade.html.

About Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Featured Article: What is the Gross Domestic Product (GDP)?

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Pundi X Tops 24 Hour Trading Volume of $3.99 Million
Pundi X Tops 24 Hour Trading Volume of $3.99 Million
PutinCoin Price Tops $0.0002 on Major Exchanges
PutinCoin Price Tops $0.0002 on Major Exchanges
Ulord  1-Day Volume Hits $455,813.00
Ulord 1-Day Volume Hits $455,813.00
BitcoinZ Hits One Day Trading Volume of $149,163.00
BitcoinZ Hits One Day Trading Volume of $149,163.00
Brokerages Set Mr. Cooper Group Inc  Price Target at $15.63
Brokerages Set Mr. Cooper Group Inc Price Target at $15.63
Welbilt, Inc  Given Consensus Recommendation of “Buy” by Brokerages
Welbilt, Inc Given Consensus Recommendation of “Buy” by Brokerages


© 2006-2019 Ticker Report